The PPAR-γ agonist pioglitazone increases neoangiogenesis and prevents apoptosis of endothelial progenitor cells

Atherosclerosis

Volumn 192, Issue 1, 2007, Pages 67-74

  Gensch, Christoph ^a   Clever, Yvonne P ^a   Werner, Christian ^a   Hanhoun, Milad ^a   Böhm, Michael ^a   Laufs, Ulrich ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Angiogenesis; Apoptosis; Endothelial progenitor cells; PPAR; Thiazolidinediones

Indexed keywords

ATAXIN 1; LECTIN; LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; VASCULOTROPIN RECEPTOR 2; WORTMANNIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BONE MARROW; CELL CULTURE; CELL FUNCTION; CELL MIGRATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN; STEM CELL; UPREGULATION; VASCULAR DISEASE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; APOPTOSIS; CELLS, CULTURED; ENDOTHELIAL CELLS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE; PPAR GAMMA; STEM CELLS; THIAZOLIDINEDIONES; UP-REGULATION;

EID: 34247368097     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.06.026     Document Type: Article

References (41)

1. Hetzel J., Balletshofer B., Rittig K., et al. Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler Thromb Vasc Biol 25 (2005) 1804-1809
2. Pfutzner A., Marx N., Lubben G., et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 45 (2005) 1925-1931
3. Pistrosch F., Passauer J., Fischer S., et al. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 27 (2004) 484-490
4. Marx N., Wohrle J., Nusser T., et al. Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation 112 (2005) 2792-2798
5. Horio T., Suzuki M., Takamisawa I., et al. Pioglitazone-induced insulin sensitization improves vascular endothelial function in nondiabetic patients with essential hypertension. Am J Hypertens 18 (2005) 1626-1630
6. Marx N. Peroxisome proliferator-activated receptor gamma and atherosclerosis. Curr Hypertens Rep 4 (2002) 71-77
7. Marx N., Duez H., Fruchart J.C., et al. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 94 (2004) 1168-1178
8. Plutzky J. Medicine. PPARs as therapeutic targets: reverse cardiology?. Science 302 (2003) 406-407
9. Asahara T., Murohara T., Sullivan A., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275 (1997) 964-967
10. Rafii S., and Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med 9 (2003) 702-712
11. Dimmeler S., Aicher A., Vasa M., et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 108 (2001) 391-397
12. Hill J.M., Zalos G., Halcox J.P., et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348 (2003) 593-600
13. Walter D.H., Rittig K., Bahlmann F.H., et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 105 (2002) 3017-3024
14. Aicher A., Heeschen C., Mildner-Rihm C., et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 9 (2003) 1370-1376
15. Strehlow K., Werner N., Berweiler J., et al. Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation. Circulation 107 (2003) 3059-3065
16. Werner N., Junk S., Laufs U., et al. Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circ Res 93 (2003) e17-e24
17. Wollert K.C., Meyer G.P., Lotz J., et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 364 (2004) 141-148
18. Shintani S., Murohara T., Ikeda H., et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 103 (2001) 2776-2779
19. Werner N., Priller J., Laufs U., et al. Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arterioscler Thromb Vasc Biol 22 (2002) 1567-1572
20. Abtahian F., Guerriero A., Sebzda E., et al. Regulation of blood and lymphatic vascular separation by signaling proteins SLP-76 and Syk. Science 299 (2003) 247-251
21. Aicher A., Zeiher A.M., and Dimmeler S. Mobilizing endothelial progenitor cells. Hypertension 45 (2005) 321-325
22. Adams V., Lenk K., Linke A., et al. Increase of circulating endothelial progenitor cells in patients with coronary artery disease after exercise-induced ischemia. Arterioscler Thromb Vasc Biol 24 (2004) 684-690
23. Laufs U., Werner N., Link A., et al. Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation 109 (2004) 220-226
24. Werner N., Kosiol S., Schiegl T., et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 353 (2005) 999-1007
25. Kojda G., Laursen J.B., Ramasamy S., et al. Protein expression, vascular reactivity and soluble guanylate cyclase activity in mice lacking the endothelial cell nitric oxide synthase: contributions of NOS isoforms to blood pressure and heart rate control. Cardiovasc Res 42 (1999) 206-213
26. Vasa M., Fichtlscherer S., Aicher A., et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 89 (2001) E1-E7
27. Heeschen C., Weis M., Aicher A., et al. A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors. J Clin Invest 110 (2002) 527-536
28. Werner N., Wassmann S., Ahlers P., et al. Circulating CD31 + /annexin V + apoptotic microparticles correlate with coronary endothelial function in patients with coronary artery disease. Arterioscler Thromb Vasc Biol (2006) Epub ahead of print
29. Spyridopoulos I., Haendeler J., Urbich C., et al. Statins enhance migratory capacity by upregulation of the telomere repeat-binding factor TRF2 in endothelial progenitor cells. Circulation 110 (2004) 3136-3142
30. Urbich C., Knau A., Fichtlscherer S., et al. FOXO-dependent expression of the proapoptotic protein Bim: pivotal role for apoptosis signaling in endothelial progenitor cells. FASEB J 19 (2005) 974-976
31. Urbich C., and Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 20 95 (2004) 343-353
32. Panigrahy D., Singer S., Shen L.Q., et al. PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 110 (2002) 923-932
33. Murata T., He S., Hangai M., et al. Peroxisome proliferator-activated receptor-gamma ligands inhibit choroidal neovascularization. Invest Ophthalmol Vis Sci 41 (2000) 2309-2317
34. Xin X., Yang S., Kowalski J., et al. Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 274 (1999) 9116-9121
35. Wang C.H., Ciliberti N., Li S.H., et al. Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropy. Circulation 109 (2004) 1392-1400
36. Pistrosch F., Herbrig K., Oelschlaegel U., et al. PPARgamma-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells. Atherosclerosis 183 (2005) 163-167
37. Verma S., Kuliszewski M.A., Li S.H., et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 109 (2004) 2058-2067
38. Fajardo L.F., Kowalski J., Kwan H.H., et al. The disc angiogenesis system. Lab Invest 58 (1988) 718-724
39. Urbich C., Dernbach E., Zeiher A.M., et al. Double-edged role of statins in angiogenesis signaling. Circ Res 90 (2002) 737-744
40. Shiomi T., Tsutsui H., Hayashidani S., et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 106 (2002) 3126-3132
41. Pereira M.P., Hurtado O., Cardenas A., et al. Rosiglitazone and 15-deoxy-delta(12,14)-prostaglandin J(2) cause potent neuroprotection after experimental stroke through noncompletely overlapping mechanisms. J Cereb Blood Flow Metab 26 (2005) 218-229